Correction
This article was originally published in The Tan Sheet
Executive Summary
In the article "Prevacid Initial Launch Efforts To Focus On Switching Prescription Users," (1"The Tan Sheet" May 18, 2009, p. 3), we inadvertently implied that Novartis intends to market Prevacid 24HR to current users of prescription Prevacid for gastroesophageal reflux disease. We should have said the firm aims to market Prevacid 24HR to the subset of its Rx patients that suffer from frequent heartburn. "The Tan Sheet" regrets the misstatement